Celtrix deal

Green Cross is responsible for the Japanese research, development and marketing of SomatoKine to treat osteoporosis, as well as for manufacturing product to support its preclinical, clinical and commercial needs in Japan.

CTRX will receive license fees, milestones and royalties. CTRX retains rights outside of Japan to SomatoKine and know-how and technology developed by Green Cross related to the manufacture of the drug as well as any product enhancements. ...